Egyptian International Pharmaceutical Investments (CAI:PHAR) PEG Ratio : N/A (As of Jun. 09, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Egyptian International Pharmaceutical Investments's PE Ratio without NRI is 5.66. Egyptian International Pharmaceutical Investments's 5-Year EBITDA growth rate is 0.00%. Therefore, Egyptian International Pharmaceutical Investments's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

The historical rank and industry rank for Egyptian International Pharmaceutical Investments's PEG Ratio or its related term are showing as below:

During the past 13 years, Egyptian International Pharmaceutical Investments's highest PEG Ratio was 6.50. The lowest was 0.33. And the median was 0.54.

CAI:PHAR's PEG Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.63
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Egyptian International Pharmaceutical Investments PEG Ratio Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments PEG Ratio Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PEG Ratio

Get a 7-Day Free Trial

0.52

2.26

0.49

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
PEG Ratio	Get a 7-Day Free Trial															-	2.89	0.69	0.51	0.49

Competitive Comparison of Egyptian International Pharmaceutical Investments's PEG Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Egyptian International Pharmaceutical Investments's PEG Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's PEG Ratio falls into.

Egyptian International Pharmaceutical Investments PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Egyptian International Pharmaceutical Investments's PEG Ratio for today is calculated as

PEG Ratio	=	PE Ratio without NRI	/	5-Year EBITDA Growth Rate*
	=	5.6565656565657	/	0.00
	=	N/A

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Egyptian International Pharmaceutical Investments (CAI:PHAR) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Egyptian International Pharmaceutical Investments PEG Ratio Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » PEG Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.